MetaCap

Apyx Medical (APYX) vs MaxCyte (MXCT)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.

Summary

Apyx Medical (APYX) has outperformed MaxCyte (MXCT) over the past year, losing 17.8% versus a loss of 40.0%. Over five years, APYX leads with a -82.1% price change compared with -90.8% for MXCT. MaxCyte is the larger company by market cap ($105.3 million vs $99.4 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

APYX-17.77%MXCT-40.00%
+76%+5%-67%
Oct 8, 20251 yearOct 8, 2026
APYX-82.84%MXCT-90.18%
+29%-35%-99%
Oct 4, 20215 yearsOct 5, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

APYX versus MXCT key metrics
MetricAPYXMXCT
Share price$2.36$1.02
Market cap$99.41M$105.27M
1-day change-7.45%-1.92%
YTD return-32.57%-34.19%
1-year return-17.77%-40.00%
5-year return-82.05%-90.75%
EPS (TTM)$-0.20$-0.34
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
52-week high$5.08$1.87
52-week low$2.32$0.643
Distance from 52-week high-53.54%-45.31%
Analyst consensusstrong_buynone
Avg. price target upside+175.42%+302.94%
Average volume127.72K668.82K
Shares outstanding42.12M103.21M
Employees20591
SectorHealthcareHealthcare
IndustryMedical DevicesMedical Devices

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • APYX has outperformed MXCT by 22.2 percentage points over the past year.

About Apyx Medical

APYX stock →

Apyx Medical Corporation, an energy technology company, designs, develops, manufactures, and sells electrosurgical equipment and medical devices in the United States and internationally. The company operates through two segments: Surgical Aesthetics and Original Equipment Manufacturing (OEM).

Healthcare · Medical Devices · 205 employees

About MaxCyte

MXCT stock →

MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.

Healthcare · Medical Devices · 91 employees

APYX vs MXCT FAQ

Which is bigger, Apyx Medical or MaxCyte?

MaxCyte (MXCT) is larger, with a market capitalization of $105.27M compared with $99.41M for Apyx Medical (APYX).

Which stock has performed better over the past year, APYX or MXCT?

APYX returned -17.77% over the past 12 months, compared with -40.00% for MXCT (price return, excluding dividends). Past performance does not predict future results.

Are Apyx Medical and MaxCyte in the same industry?

Yes. Both are classified in the Medical Devices industry within the Healthcare sector.

More comparisons